|Videos|November 26, 2013
Episode 2 - Immunotherapy in CRPC
Advertisement
Episodes in this series
During this segment, David Crawford, MD, discusses immunotherapy’s role in castration-resistant prostate cancer (CRPC), and explains how the US Food and Drug Administration’s approval of sipuleucel-T has led to a paradigm shift in the way that CRPC is treated.
Dr Crawford explains the unique capabilities of immunotherapy for advanced disease when compared to conventional treatment options such as cytotoxic chemotherapy.
Additionally, David Quinn, MD, discusses hormonal therapy agents, the key clinical trials that have tested these treatment options, and explains how the trials have demonstrated improved outcomes in CRPC.
Advertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
4
Keynote Address Tackles AI’s Role in Health Care, Eye Care
5